ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2021
Epidemiology of Left Ventricular Assist Device Infections: Findings From a Large Nonregistry Cohort.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 33 citations in OpenAlex.
- Enterococcal Infections in Left Ventricular Assist Device Recipients: Two Clinical Cases and Systematic Review.Pathogens (Basel, Switzerland) · 2026Pooled it
- EANM/SNMMI guideline/procedure standard for [European journal of nuclear medicine and molecular imaging · 2025Guideline
- The gut microbiome and allograft outcomes: implications for heart transplantation.The Journal of clinical investigation · 2026Review
- Long-term outcomes of patients implanted with a HeartMate 3 left ventricular assist device-a real-world, single-centre, observational study.ESC heart failure · 2026Observational
- Article
- The burden of left ventricular assist device (LVAD) infections on costs, lengths of stay, antimicrobial consumption and resistance: a prospective case control approach.Antimicrobial resistance and infection control · 2024Article
- Infections in Patients with Mechanical Circulatory Support.Infectious disease clinics of North America · 2024Review
- Successful Treatment of Recurrent Extensively Drug-ResistantOpen forum infectious diseases · 2024Article
- Epidemiology and Risk Factors for Nosocomial Infections in Left Ventricular Assist Device Recipients.Life (Basel, Switzerland) · 2024Article
- Infections following left ventricular assist device implantation and 1-year health-related quality of life.The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation · 2023Article
- The Impact of Obesity on T and NK Cells after LVAD Implantation.Obesity facts · 2023Article
- Continuous-flow left ventricular assist device: Current knowledge, complications, and future directions.Cardiology journal · 2022Review
- Bring it on: Top five antimicrobial stewardship challenges in transplant infectious diseases and practical strategies to address them.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2022Review
- Ventricular Assist Device-Specific Infections.Journal of clinical medicine · 2021Review
- Contemporary Management Strategies in VAD Infection.Current heart failure reports · 2020Review
- Continuous-flow left ventricular assist devices: Management in the emergency department.Journal of the American College of Emergency Physicians open · 2020Review
Corrections and comments
- Commented on by
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
backgroundInfection is a major complication during circulatory support with a left ventricular assist device (VAD). Changes in device characteristics and treatment practices in the last decade can affect the epidemiology of infection. The International Society for Heart and Lung Transplantation (ISHLT) has published recommendations on the prevention and management of VAD infections, but data to support these recommendations remain sparse.
methodsWe performed a retrospective review of 455 patients who underwent VAD placement from 2009 to 2015. Infection episodes were defined using ISHLT criteria and were also grouped as endovascular or local. Analysis included descriptive statistics.
resultsThere were 174 patients (38.6%) with a VAD infection. Infection incidence was 36.9 cases per 100 person-years of VAD support. The driveline was the most common infection site (67.2%). Systemic inflammatory response syndrome (SIRS) criteria were not satisfied in 29.2% of patients with endovascular infections, and computed tomography (CT) examinations were normal in 37.7% of cases. Gram-positive bacteria caused 65.6% of infections in patients with an available culture. Antimicrobial suppression was used in 72.3% of patients who survived treatment. Median survival after infection was 35 months for patients with VAD-related infections versus 14 months for patients with VAD-specific infections.
conclusionsVAD infections continue to be a major complication after implantation. Clinical criteria alone were not predictive of serious infections, and many patients with confirmed infection had normal CTs. Patients with VAD-specific infections had lower median survival than patients with VAD-related infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.